The 2025 APA Resource Document explores catatonia’s history, prevalence, diagnostics, differential diagnoses, and treatment—including benzodiazepines and ECT. It also addresses special populations like pediatrics, pregnancy, dementia, and outlines ethical/legal concerns.
Source : https://pubmed.ncbi.nlm.nih.gov/40602844/
Global estimates of persons in various stages of Alzheimer's disease, a form of dementia, were estimated to be at 416 million. It is estimated that 22% of people who are...
A case report of an agitated Alzheimer’s patient reveals ED nursing gaps in managing dementia-related agitation. It promotes caregiver support, palliative tools, and dignified end-of-life care resources for families.
Source : https://pubmed.ncbi.nlm.nih.gov/39974048/
These findings suggest the APOE ε4 allele influences NPS independently of and beyond its effect on ADRD.
GWAS of 12,800 MCI/ADRD participants links APOE ε4 to agitation, anxiety, apathy, delusions, and hallucinations. Findings suggest APOE influences neuropsychiatric symptoms beyond its known dementia-related effects.
Source : https://pubmed.ncbi.nlm.nih.gov/40479610/
Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial to...
The STAND feasibility trial shows that nabiximols (Sativex®) is safe, well-tolerated, and feasible for managing agitation in Alzheimer’s dementia, supporting a larger trial to assess clinical efficacy.
Source : https://pubmed.ncbi.nlm.nih.gov/40490784/
Agitation is one of the most prevalent neuropsychiatric symptoms leading to institutionalization in individuals with Alzheimer's disease (AD) dementia. It is associated with poor outcomes, including reduced functional ability, reduced...
Deuteration of dextromethorphan may impair its efficacy in treating Alzheimer's-related agitation by altering pharmacodynamics, as shown by reduced NMDA receptor blockade and clinical trial failures of AVP-786.
